- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.01. | ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study | 2 | Zacks | ||
| 06.01. | Zenas Biopharma: H.C. Wainwright bestätigt Kaufempfehlung nach positiven Studiendaten | 10 | Investing.com Deutsch | ||
| 06.01. | Why Zenas BioPharma's Selloff Was Structurally Inevitable | 8 | Benzinga.com | ||
| 06.01. | Zenas Biopharma stock maintains Buy rating at H.C. Wainwright after positive trial data | 4 | Investing.com | ||
| 06.01. | Jefferies lowers Zenas Biopharma stock price target to $48 on trial data | 3 | Investing.com | ||
| 05.01. | Zenas Biopharma stock rating downgraded by Morgan Stanley on trial results | 4 | Investing.com | ||
| 05.01. | Zenas BioPharma Stock Plummets 57% Despite Positive Phase 3 INDIGO Results | 1 | RTTNews | ||
| 05.01. | Zenas Bio Inflammation Drug Meets Phase 3 Goals, But Is It Enough to Compete With Amgen? | 10 | MedCity News | ||
| ZENAS BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 05.01. | Zenas BioPharma, A Top 1% Stock, Quadrupled In 2025. Why It Just Collapsed. | 3 | Investor's Business Daily | ||
| 05.01. | Zenas shares crash after top drug misses expectations in immune disease study | 7 | BioPharma Dive | ||
| 05.01. | Zenas BioPharma Touts Phase 3 Win, But Stock Crashes | 2 | Benzinga.com | ||
| 05.01. | Zenas' stock sinks in wake of autoimmune phase 3 data despite primary endpoint hit | 4 | FierceBiotech | ||
| 05.01. | Zenas crashes as late-stage trial data for lead asset disappoint | 5 | Seeking Alpha | ||
| 05.01. | Zenas: Phase 3 INDIGO Trial Of Obexelimab Meets Primary Endpoint | 6 | RTTNews | ||
| 05.01. | Zenas BioPharma's obexelimab shows 56% reduction in IgG4-RD flares | 2 | Investing.com | ||
| 05.01. | Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) | 187 | GlobeNewswire (Europe) | - Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare - - Obexelimab also met and demonstrated statistically... ► Artikel lesen | |
| 05.01. | Zenas BioPharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.12.25 | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 19.12.25 | Zenas BioPharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 15.12.25 | Zenas BioPharma, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 3 4 Weiter >>
71 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMGEN | 284,80 | +0,78 % | Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses | ||
| REGENERON PHARMACEUTICALS | 637,60 | -1,60 % | JPM26: Regeneron will not overpay in M&A deals amid lead asset patent expiries | ||
| BIOMARIN PHARMACEUTICAL | 48,600 | +0,89 % | BioMarin Pharmaceutical Inc.: BioMarin Appoints Arpit Davé Chief Digital and Information Officer | Mr. Davé Brings more than 20 Years of Experience in Creating Enterprise Value through Digital Transformation, Information Technology and Artificial Intelligence... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 57,50 | +1,59 % | Piper Sandler raises Arrowhead Pharma stock price target to $110 on Redemplo launch | ||
| INSMED | 139,00 | -1,42 % | INSMED INC zündet den Turbo - jetzt bloß nicht zögern! | ||
| SWEDISH ORPHAN BIOVITRUM | 31,540 | -0,57 % | SOBI: 2025 Revenue, Adj. EBITA Margin Higher Than Prior Guidance | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Swedish Orphan Biovitrum AB (SOBI.ST) announced that revenue and adjusted EBITA margin for the full year 2025 were higher than previous outlook. Full-year... ► Artikel lesen | |
| SCHOLAR ROCK | 39,600 | +1,02 % | Scholar Rock Holding Corp - 8-K, Current Report | ||
| PROQR THERAPEUTICS | 1,410 | -0,21 % | ProQR-Aktie fällt trotz positiver Studiendaten und Pipeline-Fortschritte | ||
| CRINETICS PHARMACEUTICALS | 47,800 | +0,42 % | Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral | ||
| VENTYX BIOSCIENCES | 13,865 | -0,04 % | ELI LILLY und VENTYX: Übernahmegerüchte | Die Aktie von VENTYX BIOSCIENCES legte vorgestern insgesamt 108 % zu, nachdem das Wall Street Journal über Gespräche mit ELI LILLY mit dem Ziel einer Übernahme im Volumen von mehr als 1 Mrd. $ berichtet... ► Artikel lesen | |
| THERATECHNOLOGIES | 2,780 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 06.10.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 06.10.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 06.10.2025.ISIN NameAT0000A3PGY9 UBM... ► Artikel lesen | |
| ENSYSCE BIOSCIENCES | 0,898 | -2,47 % | Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection | ~ New ADHD pipeline leverages TAAP and MPAR technologies to improve safety for patients ~ SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 8, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 37,500 | -2,85 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Provides Corporate Update | - ARCALYST- (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth -- ARCALYST 2026 net product revenue expected to be $900 - $920 million --... ► Artikel lesen | |
| TEVOGEN BIO | 0,280 | +1,82 % | Tevogen Bio Inc: Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025 | ||
| QIAGEN | 40,820 | +0,32 % | XFRA NEW INSTRUMENTS AVAILABLE ON 08.01.2026 | The following instruments on XETRA do have their first trading 08.01.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 08.01.2026
Aktien
1 US75974A1016 RENK Group AG ADR
2... ► Artikel lesen |
Das Unternehmen ZENAS BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 20,330 Euro und damit -10,00 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENAS BIOPHARMA INC finden Sie auf Wallstreet Online.